Media Database
>
Ciara Linnane

Ciara Linnane

Companies & Investing Editor at MarketWatch

Contact this person
Email address
c*****@*******.comGet email address
Influence score
66
Phone
(XXX) XXX-XXXX Get mobile number
Location
United States
Languages
  • English
Covering topics
  • Business
  • Finance & Banking Services

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place
Sign up for free

Recent Articles

marketwatch.com

COVID-19 virus may have a surprising benefit — it might shrink certain tumors

A preclinical study finds that the COVID-19 virus can trigger the development of an immune cell that can fight cancer.
marketwatch.com

Nvidia’s stock falls 3% after report of fresh issue with Blackwell ...

Blackwell GPUs are overheating when connected in custom server racks, according to a report from The Information.
marketwatch.com

RFK Jr. would rattle health markets as head of HHS, but it’s not a ...

Robert F. Kennedy Jr. would create “significantly more volatility” in health markets if he is confirmed as Secretary of Health and Human Services, making navigating policy risks far more challenging, according to Raymond James analyst Chris Meekins.
marketwatch.com

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are t...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr. his pick to head the Department of Health and Human Services.
marketwatch.com

Surging diabetes rate underscores vast opportunity in weight-loss d...

The number of adults diagnosed with diabetes has more than quadrupled since 1990 and now stands above 800 million, according to new data released in The Lancet on World Diabetes Day.
marketwatch.com

Hims & Hers’ stock tumbles on Amazon’s latest disruptive foray into...

Amazon is now offering upfront pricing for virtual care for ailments such as men’s hair loss and ED.
marketwatch.com

This biotech’s stock may double on treatment for depression, says M...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.
marketwatch.com

Schrödinger’s stock soars 9% as it enters collaboration pact with N...

Schrödinger will receive $150 million upfront plus up to $2.3 billion in milestone and royalty payments.
marketwatch.com

Can RFK Jr. really ‘run wild’ on healthcare? Investors shouldn’t pa...

Vaccine skeptic Kennedy “will not have carte blanche” to do anything he wants, analyst says.
marketwatch.com

Carl Icahn’s investment arm’s stock slides after company again halv...

Icahn Enterprises LP’s stock fell 7% early Friday, after a report that Carl Icahn’s investing arm is planning to cut its dividend to help raise the funds to expand his stake in portfolio company CVR Energy.
marketwatch.com

Moderna’s stock pops after biotech ekes out surprise profit and rev...

Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and revenue that beat estimates by a wide margin.